CUV 0.72% $14.45 clinuvel pharmaceuticals limited

Ann: Media release - First stroke patient with afamelanotide, page-11

  1. 7,705 Posts.
    lightbulb Created with Sketch. 2797
    Realistically you are looking at five years before any approval. The chance of success is <8% (on average).

    The median phase III trial in their data set cost $21.4 million, they reported last year in Nature Reviews Drug Discovery. The median phase II trial cost $8.6 million, and the median phase I trial cost $3.4 million, they also reported.

    https://www.nature.com/articles/nrd.2018.198

    From the FDA

    Step 3: Clinical Research



    Phase 2

    Study Participants:Up to several hundred people with the disease/condition.

    Length of Study: Several months to 2 years

    Approximately 33% of drugs move to the next phase



    Phase 3

    Study Participants:300 to 3,000 volunteers who have the disease or condition

    Length of Study: 1 to 4 years

    Approximately 25-30% of drugs move to the next phase





    https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$14.45
Change
-0.105(0.72%)
Mkt cap ! $725.1M
Open High Low Value Volume
$14.60 $14.60 $14.32 $259.4K 17.91K

Buyers (Bids)

No. Vol. Price($)
7 194 $14.43
 

Sellers (Offers)

Price($) Vol. No.
$14.46 37 2
View Market Depth
Last trade - 11.52am 10/09/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.